2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia

Authors, Journal, Affiliations, Type, DOI

• Richard L. Page, José A. Joglar, Mary A. Caldwell, Hugh Calkins, et al.
• Circulation / Journal of the American College of Cardiology / Heart Rhythm Journal (co-published)
• American College of Cardiology, American Heart Association, Heart Rhythm Society
• Type: Multi-society clinical practice guideline
• DOI: 10.1161/CIR.0000000000000311

Overview

The 2015 ACC/AHA/HRS SVT guideline is the comprehensive multi-society reference for management of all supraventricular tachycardias except atrial fibrillation in adults. It establishes a hierarchical acute management framework (vagal maneuvers → adenosine → IV CCBs/beta-blockers → cardioversion) and designates catheter ablation as first-line definitive therapy for symptomatic AVNRT and AVRT. The critical safety principle is that AV nodal blocking agents are Class III/Harm in pre-excited AF (WPW + AF), as they can accelerate conduction over the accessory pathway and precipitate ventricular fibrillation. The guideline provides class-graded recommendations for AVNRT, AVRT, focal/multifocal AT, atrial flutter, IST, junctional tachycardia, and special populations (pediatrics, ACHD, pregnancy, elderly).

Keywords

Supraventricular tachycardia, paroxysmal supraventricular tachycardia, AVNRT, AVRT, atrial tachycardia, atrial flutter, Wolff-Parkinson-White, accessory pathway, pre-excitation, catheter ablation, vagal maneuvers, adenosine, inappropriate sinus tachycardia, multifocal atrial tachycardia, junctional tachycardia

Key Takeaways

Mechanisms and Definitions (Section 2.1)

• SVT = tachycardias where the mechanism involves tissue from the His bundle or above; excludes AF for guideline purposes
• PSVT (paroxysmal SVT) = subset characterized by abrupt onset and termination; typical of AVNRT/AVRT
• AVNRT: most common SVT; reentrant circuit using fast and slow AV nodal pathways; typical = slow-fast (anterograde slow, retrograde fast); >60% in women
• AVRT: reentrant circuit requiring accessory pathway, atrium, AV node, and ventricle; orthodromic (narrow) >90%, antidromic (wide) ~5%
• Focal AT: localized atrial origin; centrifugal spread; 3–17% of ablation referrals
• MAT: ≥3 distinct P-wave morphologies; always irregular; typically associated with pulmonary disease
• Atrial flutter: macroreentrant; CTI-dependent (typical/reverse typical) vs non-CTI-dependent (atypical)
• Junctional tachycardia: enhanced automaticity from AV junction; uncommon in adults
• WPW syndrome: pre-excitation on ECG + documented SVT or consistent symptoms

Epidemiology (Section 2.2)

• SVT prevalence: 2.29 per 1,000 persons in general population
• PSVT incidence: ~36 per 100,000/year; ~89,000 new cases/year; ~570,000 patients with PSVT in the US
• Women have 2× the risk of PSVT vs men; individuals >65 have >5× the risk of younger persons
• AVNRT more common in women and middle-aged/older patients; AVRT more common in younger patients
• Pre-excitation (WPW pattern) prevalence: 0.1%–0.3% of general population; SCD risk 0.15%–0.24% over 10 years in manifest accessory pathways

Acute Treatment of Unknown Mechanism SVT (Section 2.4.1)

• Class I/B-R: Vagal maneuvers (Valsalva, carotid sinus massage) — first-line intervention; Valsalva more effective than carotid sinus massage; overall success rate 27.7% when combined
• Class I/B-R: Adenosine — 6 mg rapid IV bolus; repeat 12 mg ×2 if no response; success 78%–96% for AVNRT/AVRT; use proximal IV with saline flush; also diagnostic for atrial flutter/AT
• Class I/B-NR: Synchronized cardioversion for hemodynamically unstable SVT when vagal/adenosine fail or not feasible
• Class I/B-NR: Synchronized cardioversion for hemodynamically stable SVT when pharmacological therapy fails or is contraindicated
• Class IIa/B-R: IV diltiazem or verapamil for hemodynamically stable SVT (64%–98% termination); NEVER in VT, pre-excited AF, or suspected systolic HF
• Class IIa/C-LD: IV beta blockers for hemodynamically stable SVT

Ongoing Management of Unknown Mechanism SVT (Section 2.4.2)

• Class I/B-R: Oral beta blockers, diltiazem, or verapamil for symptomatic SVT without ventricular pre-excitation
• Class I/B-NR: EP study with option for ablation — first-line definitive therapy; large registries: >95% success for AVNRT/AVRT ablation, <1% risk of AV block
• Class I/C-LD: Patient education on vagal maneuvers
• Class IIa/B-R: Flecainide or propafenone for patients without structural/ischemic heart disease (86–93% freedom from recurrence at 12 months)
• Class IIb/B-R: Sotalol; Class IIb/B-R: Dofetilide; Class IIb/C-LD: Amiodarone; Class IIb/C-LD: Digoxin (all as third-line alternatives for non-ablation candidates)

AVNRT (Section 5)

• Most common SVT; dual AV nodal physiology substrate; rates 110–250+ bpm; usually well tolerated
• Polyuria common due to elevated right atrial pressure and ANP; "neck pounding" from cannon a-waves
• Acute (Class I/B-R): Vagal maneuvers → adenosine → cardioversion if hemodynamically unstable or pharmacotherapy fails
• Acute (Class IIa/B-R): IV beta blockers, diltiazem, or verapamil for hemodynamically stable patients
• Ongoing (Class I/B-NR): Catheter ablation of slow pathway — preferred first-line definitive therapy; >95% success; <1% AV block risk; cryoablation alternative with lower AV block risk but higher recurrence
• Ongoing (Class I/B-R): Oral verapamil or diltiazem for patients not pursuing ablation
• Ongoing (Class IIa/B-NR): Observation without treatment is reasonable for minimally symptomatic AVNRT (nearly half improved over 15 years without therapy)
• Ongoing (IIb/C-LD): "Pill-in-the-pocket" oral beta blocker/diltiazem/verapamil for infrequent well-tolerated episodes (syncope observed in some patients)

AVRT and Accessory Pathways (Section 6)

• Orthodromic AVRT: narrow complex (AV node anterograde, accessory pathway retrograde); 90–95% of AVRT
• Antidromic AVRT: wide complex (accessory pathway anterograde, AV node retrograde); ~5%
• Acute orthodromic AVRT (Class I): Vagal maneuvers → adenosine → cardioversion if unstable
• Acute orthodromic AVRT (Class IIa/B-R): IV diltiazem/verapamil/beta blockers if no pre-excitation on resting ECG
• Acute pre-excited AF (Class I): Synchronized cardioversion or ibutilide/procainamide
• CLASS III/HARM: IV digoxin, amiodarone, beta-blockers, diltiazem, verapamil in pre-excited AF — may accelerate ventricular rate over accessory pathway → VF
• Ongoing (Class I/B-NR): Catheter ablation of accessory pathway — first-line; ~93–95% success; 3% major complications; effective for PJRT and Mahaim fibers
• Ongoing (Class I/C-LD): Oral beta blockers/diltiazem/verapamil for concealed accessory pathway (no pre-excitation)
• Ongoing (Class IIa/B-R): Flecainide or propafenone without structural/ischemic heart disease
• Ongoing (Class III/Harm): Oral digoxin in AVRT or AF with pre-excitation — shortens accessory pathway refractoriness → VF risk

Asymptomatic Pre-Excitation / WPW Risk Stratification (Section 6.2–6.3)

• SCD risk: 10-year risk 0.15%–0.24%; highest in first 2 decades of life
• Low-risk markers: Abrupt loss of pre-excitation on exercise testing (Class I/B-NR) or intermittent loss on ECG/Holter (Class I/C-LD) — ~90% PPV for pathway incapable of rapid conduction
• Class IIa/B-NR: EP study for risk stratification in asymptomatic pre-excitation; high-risk EP findings: shortest pre-excited R-R interval <250 ms during induced AF, multiple accessory pathways, accessory pathway ERP <240 ms, AVRT precipitating pre-excited AF
• Class IIa/B-NR: Catheter ablation if EP study identifies high-risk pathway (one RCT: arrhythmic events 7% ablation vs 77% no ablation); also reasonable if employment requires it (e.g., pilots)
• Class IIa/B-NR: Observation without further evaluation is also reasonable (great majority have benign course)

Focal Atrial Tachycardia (Section 4.1)

• Atrial rate 100–250 bpm; represents 3–17% of ablation referrals; AT-mediated cardiomyopathy in up to 10% of incessant AT
• P-wave morphology predicts origin: positive P in V1 + negative in I/aVL = left atrial origin; positive in inferior leads = cranial origin
• Acute (Class I/C-LD): IV beta blockers, diltiazem, or verapamil
• Ongoing (Class I/B-NR): Catheter ablation — acute success >90–95% at experienced centers; <1–2% complications; full EF recovery in 97% after ablation of cardiomyopathy-associated AT

Multifocal Atrial Tachycardia (Section 4.2)

• ≥3 distinct P-wave morphologies; irregular; associated with pulmonary disease, hypomagnesemia, theophylline
• First-line: treat underlying condition + IV magnesium even with normal Mg levels
• Class IIa/C-LD: IV metoprolol or verapamil for acute treatment; cardioversion NOT useful
• Ongoing: Oral verapamil (Class IIa/B-NR) or diltiazem (Class IIa/C-LD) for rate control; antiarrhythmics generally not helpful

Atrial Flutter (Section 7)

• CTI-dependent (typical/reverse typical): typical shows sawtooth waves in II/III/aVF, positive V1; atrial rate 250–350 bpm
• Non-CTI-dependent (atypical): after cardiac surgery/AF ablation; more complex mapping required
• Thromboembolism risk mirrors AF; anticoagulation recommended per same CHA₂DS₂-VA framework (Class I/B-NR)
• Acute (Class I/A): Dofetilide oral or ibutilide IV for pharmacological cardioversion (~60% conversion with ibutilide); risk of TdP — magnesium pretreatment improves safety/efficacy
• Acute (Class I/B-R): IV beta blockers, diltiazem, or verapamil for rate control
• Acute (Class I/B-NR): Elective synchronized cardioversion; rapid atrial pacing if leads in place
• Ongoing (Class I/B-R): CTI ablation — success >97%; also preferred when flutter induced by flecainide/propafenone/amiodarone use for AF
• Rate control often difficult in flutter (less concealed AV nodal conduction); higher doses of AV nodal agents may be needed
• After CTI ablation, 22–50% develop AF within 14–30 months; risk factors: prior AF, LV dysfunction, large LA

IST (Section 3.2)

• Diagnosis of exclusion; resting HR >100 bpm + mean 24h HR >90 bpm + debilitating symptoms; no physiological basis
• Class I/C-LD: Evaluate and treat reversible causes first
• Class IIa/B-R: Ivabradine — reduces daytime HR from 98 to 85 bpm; complete symptom resolution in many; superior to metoprolol in 1 observational study; side effect: phosphenes 3%
• Class IIb/C-LD: Beta blockers (modest HR reduction, dose limited by hypotension); combination with ivabradine may be reasonable
• Sinus node RF ablation: modest benefit, significant complications (pacemaker required, phrenic nerve injury, SVC syndrome); reserved for highly symptomatic patients who fail medication

Junctional Tachycardia (Section 8)

• Enhanced automaticity from AV junction; uncommon in adults; rates 120–220 bpm; AV dissociation may be present
• Acute/Ongoing (Class IIa/C-LD): IV/oral beta blockers, diltiazem, or verapamil
• Catheter ablation: 82–85% success; 5–10% risk of AV block; generally reserved for drug-refractory cases

Special Populations (Section 9)

Pediatrics:

• Accessory pathway–mediated tachycardia >70% of SVT in infants; AVNRT increases with age
• Higher adenosine doses needed in children (150–250 mcg/kg)
• Digoxin AVOIDED in pre-excitation (associated with SCD/VF in infancy)
• Catheter ablation: comparable success to adults, higher complication risk <15 kg; recurrence 7–17%

ACHD:

• SVT in 10–20% of ACHD; macroreentrant AT (flutter) >75% of mechanisms
• Catheter ablation: 70–85% acute success; 20–60% recurrence within 2 years; highest success in repaired ASD (90–100%)
• Hemodynamic assessment mandatory; structural repair and arrhythmia treatment must be integrated

Pregnancy:

• New SVT onset in 3.9% of women during pregnancy; 22% with existing SVT have worsened symptoms
• Vagal maneuvers and adenosine safe in pregnancy; metoprolol for ongoing management
• Digoxin, flecainide, sotalol with documented safety; drugs to avoid: atenolol, amiodarone (avoid chronically)

Elderly:

• PSVT incidence >5× higher in >65 years; AVNRT rates generally slower; higher syncope/near-syncope risk
• AV nodal–blocking drugs effective but dose titration critical; ablation equally effective

Ablation Outcomes (Table 8)

ECG Principles (Section 2.3.2)

• Narrow QRS SVT algorithm: regular or irregular? → atrial rate vs ventricular rate? → RP interval (short vs long)?
• Short RP (<90 ms): AVNRT (pseudo-S in inferior leads, pseudo-R' in V1), orthodromic AVRT (P in early ST segment)
• Long RP: AT (P before QRS but after T wave), atypical AVNRT (fast-slow), PJRT (slowly conducting posteroseptal AP)
• WCT: VT = AV dissociation, fusion beats, precordial concordance; Brugada criteria (V1-V6 R-S absence or R-S interval >100 ms); Vereckei algorithm (aVR initial R or Q >40 ms, notch on descending limb)
• Treatment of VT as SVT (verapamil/diltiazem for VT) = potentially lethal; when in doubt, assume VT

Limitations of the Document

• Evidence review through May 2015; several practices now updated (e.g., post-modified Valsalva maneuver data, newer ablation technologies including pulsed-field ablation)
• Most RCT data limited to AVNRT/AVRT; focal AT, MAT, IST, and junctional tachycardia management relies primarily on observational data
• Special populations (pregnancy, elderly, ACHD) guidance is largely expert consensus with limited RCT evidence
• Pediatric recommendations extrapolated to adolescents; no formal pediatric-specific recommendations
• Cost-effectiveness and QOL data insufficient for formal recommendations

Key Concepts Mentioned

• concepts/SVT-Management — core guideline framework
• concepts/AVNRT — most common SVT; slow-pathway ablation first-line
• concepts/AVRT-Accessory-Pathway — orthodromic/antidromic AVRT, WPW, pre-excited AF
• concepts/Inappropriate-Sinus-Tachycardia — IST diagnosis, ivabradine role
• concepts/Wide-Complex-Tachycardia — VT vs SVT differentiation principles
• concepts/Antiarrhythmic-Drugs — drug tables for acute/ongoing SVT management

Key Entities Mentioned

• entities/Atrial-Flutter — CTI-dependent and non-CTI-dependent flutter management
• entities/Atrial-Fibrillation — pre-excited AF; anticoagulation for flutter mirrors AF

Wiki Pages Updated

• wiki/sources/svt-aha-2015.md (created)
• wiki/concepts/SVT-Management.md (created)
• wiki/concepts/AVNRT.md (created)
• wiki/concepts/AVRT-Accessory-Pathway.md (created)
• wiki/entities/Atrial-Flutter.md (updated)
• wiki/concepts/Inappropriate-Sinus-Tachycardia.md (updated)
• wiki/concepts/Wide-Complex-Tachycardia.md (updated)
• wiki/sourceindex.md (updated)
• wiki/wikiindex.md (updated)
• log.md (updated)